Cancer Genetics Reports Second Quarter 2018 Financial Results and Provides Strategic Business Updates

Conference call at 8:30 a.m. ET, Tuesday, August 14, 2018

RUTHERFORD, N.J., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced financial and operating results for the second quarter ended June 30, 2018 as well as an update on its strategic direction and key organizational initiatives.

John A. Roberts, Chief Executive Officer of Cancer Genetics said, “During the second quarter of 2018, we made significant advances in reorienting the company and are continuing to take the necessary steps to increase the efficiency of our overall business portfolio and accelerate our path to profitability.

“We are making good progress in consolidating the operations of our West Coast molecular profiling laboratory and moving these capabilities to our facilities in New Jersey and North Carolina. We believe that the consolidation of the Los Angeles facility will reduce our operating expenses, making a positive contribution towards our cost structure consistent with our growth and transformation strategy for 2018 and beyond.”

Mr. Roberts added, “To supplement our efforts aimed at growing our biopharma business, we strengthened our management team with the appointment of Michael McCartney as the company’s Chief Commercial Officer. Michael will be responsible for overseeing our commercial strategy and leading the Company’s business development initiatives. To that end, I am particularly pleased with the recent developments in our biopharma channel strategy with an increased velocity of project work with our channel partner firms.   We have a solid, collaborative foundation stemming from previous partnership agreements signed in 2016, and have recently begun expanding the scope of our work with these partners.”

Mr. Roberts concluded, “On the financial front, we recently completed a convertible note financing and raised $2.5 million to support the execution of our 2018 transformation and strategic plan to reorganize our business and position the company for future growth. Further, our engagement with Raymond James as a financial advisor in evaluating strategic options continues to progress, as we have been engaged in discussions regarding several potential transactions and hope to make an announcement concerning these developments in the near future. Overall, we are committed to executing on our growth strategy and remain focused on making CGI a premier company in the precision oncology arena.”


  • Strengthened leadership team with appointment of Michael McCartney as Chief Commercial Officer.
  • Completed sale of wholly-owned subsidiary BioServe Biotechnologies (India) Private Limited to REPROCELL for $1.9 million in April 2018.
  • Raised $2.5 million through a convertible note financing in July 2018.
  • Progressed the consolidation of the West Coast molecular profiling laboratory and relocation of most of these activities to New Jersey and North Carolina laboratories, as part of 2018 transformation strategy. The consolidation of this facility is currently expected to be complete by the end of the third quarter, and reduce operating expenses by over $4 million annually once completed.          


The Company reported total revenue of $7.0 million for the second quarter of 2018 compared to revenue of $6.6 million in second quarter of 2017, an increase of 7% or $0.4million.

Biopharma services revenue totaled $3.6 million in the second quarter, compared to $3.3 million during the second quarter 2017. Biopharma projects are dependent on the timing, size and duration of our contracts with pharmaceutical and biotech companies and clinical research organizations, and can fluctuate in comparable periods. The Company increased the number of clinical studies and trials it is supporting to 342, up from 170 in Q2 2017. The Company’s booking-to-billing ratio for Q2 2018 was 2.5.

​Clinical Services revenue decreased by approximately $1 million in the second quarter of 2018 compared to the same period in 2017, from $3.1 million to $2.1 million.

The Company’s Discovery Services contributed $1.3 million in revenue for the second quarter of 2018 driven by our acquisition of vivoPharm in August of 2017. This represents an increase of approximately $1.0 million as compared to $0.3 million in revenue for the second quarter of 2017.

Gross profit margin was 31% or $2.2 million in Q2 2018, compared to 39% or $2.6 million in the second quarter 2017.

Total operating expenses for the second quarter of 2018 were approximately $7.4 million, an increase of 30% compared to $5.7 million during the second quarter of 2017, principally due to restructuring costs of $0.7 million, an increase in our professional fees of $0.5 million related to recent financing and M&A activities, an increase in our bad debt expense of $0.2 million, and an increase in our selling expenses of $0.1 million.

Net loss was $3.6 million or $0.13 per share for the second quarter of 2018, compared to a net loss of $2.8 million or $0.16 per share for the second quarter of 2017. 

Cash and cash equivalents as of June 30, 2018 totaled $1.6 million, compared to $4.0 million as of March 31, 2018. In July 2018, the Company closed a convertible note financing generating net proceeds of approximately $2.5 million.

As announced previously, the Company engaged Raymond James & Associates, Inc. as a financial advisor to assist with evaluating options for the Company’s strategic direction. These options may include raising additional capital, the acquisition of another company and / or complementary assets, the sale of the Company, or another type of strategic partnership.

Tuesday, August 14, 2018, 8:30 a.m. Eastern Time
Domestic: 800-289-0438
International: 323-794-2423
Conference ID:1766530
Replay – Available through August 28, 2018 
Domestic: 844-512-2921
International: 412-317-6671
Conference ID: 1766530


Cancer Genetics, Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, Australia and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.

The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.

For more information, please visit or follow CGI at:


Twitter: @Cancer_Genetics


Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Cancer Genetics Inc.’s expectations regarding future financial and/or operating results and potential for our tests and services, and future revenues or growth in this press release constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from consolidation efforts and/or acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, uncertainties with respect to evaluating strategic options, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2017 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.


Lee Roth
The Ruth Group
Tel: 646-536-7012

Kirsten Thomas
The Ruth Group
Tel: 508-280-6592

Cancer Genetics, Inc. and Subsidiaries
Consolidated Balance Sheets (Unaudited)
(in thousands, except par value)
 June 30,
 December 31,
Cash and cash equivalents$1,601  $9,541 
Accounts receivable, net of allowance for doubtful accounts of 2018 $7,401; 2017 $6,5399,357  10,958 
Other current assets3,245  2,707 
    Total current assets14,203  23,206 
FIXED ASSETS, net of accumulated depreciation4,742  5,550 
Restricted cash350  350 
Patents and other intangible assets, net of accumulated amortization4,276  4,478 
Investment in joint venture243  246 
Goodwill17,257  17,992 
Other300  399 
    Total other assets22,426  23,465 
Total Assets$41,371  $52,221 
Accounts payable and accrued expenses$9,778  $8,715 
Obligations under capital leases, current portion322  272 
Deferred revenue2,004  516 
Line of credit3,438  4,137 
Term note, current portion6,000  6,000 
    Total current liabilities21,542  19,640 
Obligations under capital leases564  624 
Deferred rent payable and other304  360 
Warrant liability1,134  4,403 
Deferred revenue, long-term547  429 
Total Liabilities24,091  25,456 
Preferred stock, authorized 9,764 shares, $0.0001 par value, none issued   
Common stock, authorized 100,000 shares, $0.0001 par value, 27,726 and 27,754 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively3  3 
Additional paid-in capital162,575  161,527 
Accumulated other comprehensive income134  69 
Accumulated (deficit)(145,432) (134,834)
Total Stockholders’ Equity17,280  26,765 
Total Liabilities and Stockholders’ Equity$41,371  $52,221 

Cancer Genetics, Inc. and Subsidiaries
Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited)
(in thousands, except per share amounts)
 Three Months Ended June 30, Six Months Ended June 30,
 2018 2017 2018 2017
Revenue$7,036  $6,604  $14,703  $13,570 
Cost of revenues4,853  4,034  9,935  8,243 
    Gross profit2,183  2,570  4,768  5,327 
Operating expenses:       
Research and development673  989  1,354  2,099 
General and administrative5,419  3,529  10,679  7,006 
Sales and marketing1,341  1,165  2,932  2,136 
    Total operating expenses7,433  5,683  14,965  11,241 
    Loss from operations(5,250) (3,113) (10,197) (5,914)
Other income (expense):       
Interest expense(577) (253) (816) (447)
Interest income(1) 10  20  27 
Change in fair value of acquisition note payable64  13  81  (219)
Change in fair value of warrant liability2,154  577  2,846  (6,717)
Other income (expense)(23)   (23) (46)
    Total other income (expense)1,617  347  2,108  (7,402)
    Loss before income taxes(3,633) (2,766) (8,089) (13,316)
Income tax (benefit)      (970)
    Net (loss)$(3,633) $(2,766) $(8,089) $(12,346)
Basic net (loss) per share$(0.13) $(0.14) $(0.30) $(0.64)
Diluted net (loss) per share$(0.13) $(0.16) $(0.30) $(0.64)
Basic weighted-average shares outstanding27,049  19,697  27,049  19,301 
Diluted weighted-average shares outstanding27,049  20,663  27,049  19,301 
Net (loss)(3,633) (2,766) (8,089) (12,346)
  Foreign currency translation gain85    65   
Comprehensive (loss)(3,548) (2,766) (8,024) (12,346)